share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

SEC announcement ·  Jun 6 04:13
Summary by Futu AI
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.